Young David 4

What Happened
David Young, President of Research & Development and a director at Processa Pharmaceuticals (PCSA), made an open-market purchase of 1,545 shares on 2026-05-15 at $2.97 per share, for a total of about $4,589. This was a straight purchase (transaction code P), which is generally considered a bullish signal compared with sales but is modest in dollar size.

Key Details

• Transaction date and price: 2026-05-15 — 1,545 shares at $2.97 per share (total ≈ $4,589).
• Transaction type: Open-market purchase (Code P).
• Shares owned after transaction: Not specified in the provided filing.
• Filing timeliness: Form 4 was filed on 2026-05-19 for the 2026-05-15 trade (filed within the Form 4 reporting deadline).
• Footnote: The filing corrects immaterial errors from a May 1, 2026 Form 4 — the April 30, 2026 purchase price was corrected to $2.71 (not $2.69), reducing that April 30 purchase by 13 shares (Footnote F1).
• No option exercises, grants, tax-withholding, or 10b5-1 plan specified in this report.

Context
This was a simple open-market buy of common shares (not an option exercise or award). The amount is relatively small (~$4.6K), so while insider purchases can be meaningful, the modest size limits how much weight investors should place on it by itself. The corrected prior filing is an immaterial bookkeeping adjustment and does not change the nature of the current purchase.